Intellia lands up to $400M debt deal with OrbiMed ahead of CRISPR drug launch
What's the deal? Intellia Therapeutics has secured a non-dilutive senior secured term loan facility of up to $400 million with healthcare investor OrbiMed. The Cambridge, Massachusetts-based company is a clinical-stage biopharmaceutical focused on CRISPR gene editing.
How it's structured: An initial $75 million term loan was funded at closing. Five further tranches totaling up to $225 million can be drawn subject to milestones tied mainly to Intellia's lead candidate, with another $100 million available by mutual agreement over the five-year term.
Why now? The financing arrives as Intellia moves toward a planned US approval and commercial launch of lonvoguran ziclumeran (lonvo-z), a one-time CRISPR treatment for hereditary angioedema (HAE). Being non-dilutive, it lets the company fund that push without issuing new equity.
What's the endgame? Lonvo-z aims to permanently lower kallikrein with a single outpatient dose, and could become the first one-time treatment for HAE. It has secured five regulatory designations, including Orphan Drug and RMAT status from the US Food and Drug Administration.
Beyond HAE, the facility supports Intellia's second candidate, nexiguran ziclumeran, in transthyretin amyloidosis, plus early pipeline work.
What they're saying: "This non-dilutive financing enables us to more freely execute our plan to successfully launch lonvo-z in HAE," said chief financial officer Edward Dulac. OrbiMed general partner Matthew Rizzo called Intellia "a well-recognized leader in the in vivo gene editing revolution."
TD CowenDealroom has a profile for this one. Try Dealroom → advised Intellia on the transaction, with Goodwin ProcterDealroom has a profile for this one. Try Dealroom → as legal advisor. Covington & BurlingDealroom has a profile for this one. Try Dealroom → advised OrbiMed.
The signal: At up to $400 million, the facility ranks among the larger financings in its class, signaling investor confidence in Intellia as it shifts from clinical development toward commercialisation. For CRISPR firms, debt tied to product milestones marks a step from research bets to revenue-driven business.
Image credit: clembore
